儿童急性早幼粒细胞白血病（APL）与良好的初始预后相关。然而,微小残留病(MRD)随访仍不明确，复发病例因其复发性而令人担忧。因此，我们报告了两种基于聚吡咯（PPy）和石墨烯量子点（GQD）的电化学柔性基因传感器，用于无标记的PML-RARα癌基因检测。原子力显微镜(AFM),扫描电子显微镜（SEM），循环伏安法（CV），和电化学阻抗谱（EIS）用于表征技术生物传感器的发展。将M7和APLB寡核苷酸序列用作生物受体以分别检测染色体15和17上的致癌片段。AFM表征显示，当使用阳性患者样品进行测试时，传感器层具有最大高度峰的异质地形表面。APLB/Genosensor表现出阳极峰值电流（ΔI）的百分比变化为423％。对于更浓缩的cDNA样品，M7/Genosensor的ΔI为61.44％。所描述的行为与所提出的生物传感器的生物特异性识别相关联。APLB/Genosensor和M7/Genosensor的检测极限（LOD）为0.214pM和0.677pM，分别。APLB/Genosensor和M7/Genosensor的定量限（LOQ）为0.648pM和2.05pM，分别。基因传感器显示出可重复性，APLB的相对标准偏差为7.12％，M7的相对标准偏差为1.18％，重复性高（APLB为9.89％，M7为1.51％）。此外,遗传工具可以鉴定纯化样品中的PML-RARα癌基因，质粒,以及诊断为具有高生物分析性能的APL的儿科患者的临床标本。因此,生物传感器是临床诊断APL和监测MRD的一种有价值的替代方法，对公众健康有影响。
Acute promyelocytic leukemia (APL) in children is associated with a favorable initial prognosis. However, minimal residual disease (MRD) follow-up remains poorly defined, and relapse cases are concerning due to their recurrent nature. Thus, we report two electrochemical flexible genosensors based on polypyrrole (PPy) and graphene quantum dots (GQDs) for label-free PML-RARα oncogene detection. Atomic force microscopy (AFM), scanning electron microscope (SEM), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS) were used to characterize the technological biosensor development. M7 and APLB oligonucleotide sequences were used as bioreceptors to detect oncogenic segments on chromosomes 15 and 17, respectively. AFM characterization revealed heterogeneous topographical surfaces with maximum height peaks for sensor layers when tested with positive patient samples. APLB/
Genosensor exhibited a percentage change in anode peak current (ΔI) of 423 %. M7/
Genosensor exhibited a ΔI of 61.44 % for more concentrated cDNA samples. The described behavior is associated with the biospecific recognition of the proposed biosensors. Limits of detection (LOD) of 0.214 pM and 0.677 pM were obtained for APLB/
Genosensor and M7/
Genosensor, respectively. The limits of quantification (LOQ) of 0.648 pM and 2.05 pM were estimated for APLB/
Genosensor and M7/
Genosensor, respectively. The genosensors showed reproducibility with a relative standard deviation of 7.12 % for APLB and 1.18 % for M7 and high repeatability (9.89 % for APLB and 1.51 % for M7). In addition, genetic tools could identify the PML-RARα oncogene in purified samples, plasmids, and clinical specimens from pediatric patients diagnosed with APL with high bioanalytical performance. Therefore, biosensors represent a valuable alternative for the clinical diagnosis of APL and monitoring of MRD with an impact on public health.
